Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.36−0.04 (-8.94%)
Close on Nov 17, 2026Market cap $87.79MP/E –Yield –
Outlook Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Outlook Therapeutics's total debt was $967.06M at Jun 30, 2020. For fiscal 2019 it was $1.08B, up 652426.3% from the year before. The highest annual figure on record is $1.08B in fiscal 2019.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Sep 30, 2019 | $1.08B | +652426.3% |
| FY2018 | Sep 30, 2018 | $164.97K | -19.0% |
| FY2017 | Sep 30, 2017 | $203.71K | -92.8% |
| FY2016 | Sep 30, 2016 | $2.82M | -23.1% |
| FY2015 | Sep 30, 2015 | $3.67M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $967.06M | +673862.3% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $1.08B | +652426.3% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $1.11M | +460.6% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $1.13M | +388.9% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $143.49K | -45.3% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $164.97K | -19.0% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $198.28K | -8.1% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $230.69K | -8.8% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $262.25K | -13.1% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $203.71K | -92.8% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $215.76K | -71.3% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $253.07K | -66.7% |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $301.63K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $2.82M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $752.45K | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | $760.01K | – |
See a number that looks wrong?